Abstract 307P
Background
Uterine leiomyosarcoma (uLMS) is a rare, aggressive subtype of uterine cancer. Metastatic uLMS is known for its poor prognosis. uLMS have recurrence rates of 50-70%, with an overall 5-year survival less than 15% in advanced stages. The main treatment for localized uLMS is surgery. For unresectable or advanced uLMS, other options such as chemotherapy and hormonal therapy can be offered.
Methods
We conducted a search across 5 databases, Google Scholar, Science Direct, PubMed, EMBASE & Scopus for studies within the last 15 years. We included studies that recorded combination chemotherapy/hormonal therapy as the treatment regime for histologically confirmed metastatic/unresectable uLMS. We excluded studies with <5 samples, those that included other uterine cancers & non-English articles. Quality of the studies were assessed by the Newcastle-Ottawa Scale (NOS).
Results
We found 10 studies, with a total of 427 metastatic uLMS patients. Combination chemotherapy had much higher rates of response & progression-free survival compared to hormonal therapy. Gemcitabin-docetaxel was the most common regime, with high effectivity. Addition of targeted therapy did not improve outcomes significantly. However, combination chemotherapy had a much higher proportion of grade 3-4 toxicity. Most common side effects were myelosuppression, fatigue & liver toxicity, resulting in much higher rates of therapy discontinuation due to the side effects. Hormonal therapy was much more tolerable, with common side effects including hot flashes, weight gain, muscle pain & joint pain. Unfortunately, hormonal therapy had higher proportions of therapy discontinuation due to disease progression, and had lower response rates, shorter overall survival & progression-free survival. Overall, patient-specific factors play a crucial role in treatment decisions. Hormonal therapy has a more attractive side effect profile, while combination chemotherapy though more aggressive may be favorable in cases requiring rapid tumor control.
Conclusions
uLMS is an aggressive cancer with hormonal therapy & combination chemotherapy as treatment options. Hormonal therapy has a better side effect profile, with chemotherapy having better effectivity and survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P. Angel.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract